Q3 2021 13F Holders as of 9/30/2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
106M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
1.86M
-
Shares change
-
-31.8K
-
Total reported value, excl. options
-
$17.1M
-
Value change
-
-$844K
-
Put/Call ratio
-
0.59
-
Number of buys
-
18
-
Number of sells
-
-11
-
Price
-
$9.16
Significant Holders of SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) as of Q3 2021
43 filings reported holding SLS - SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
SELLAS Life Sciences Group, Inc. - Common Stock, par value $0.0001 per share (SLS) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.86M shares
of 106M outstanding shares and own 1.76% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (651K shares), BlackRock Inc. (253K shares), MORGAN STANLEY (185K shares), GEODE CAPITAL MANAGEMENT, LLC (134K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (113K shares), BANK OF MONTREAL /CAN/ (110K shares), Equitable Holdings, Inc. (100K shares), BANK OF AMERICA CORP /DE/ (43.9K shares), CITADEL ADVISORS LLC (42.5K shares), and STATE STREET CORP (37.5K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.